Skip to main content
Erschienen in: Drugs & Aging 4/2015

01.04.2015 | Review Article

Optimal Differentiated Thyroid Cancer Management in the Elderly

verfasst von: Donald S. A. McLeod, Kelly Carruthers, Dev A. S. Kevat

Erschienen in: Drugs & Aging | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

The incidence of differentiated thyroid cancer is increasing worldwide across all age groups. While most patients with differentiated thyroid cancer have a good prognosis, aggressive disease is more common in the elderly and disease-specific mortality is higher. Treatment options for differentiated thyroid cancer include surgery, levothyroxine, radioactive iodine, external beam radiotherapy and kinase inhibitors. Rational and evidence-based management is particularly important in older individuals because they may experience greater toxicities from the therapeutic options. We advocate an explicit risk–benefit analytic approach to thyroid cancer care that emphasises individual patient factors, likely disease biology and progression, and age-dependent treatment characteristics to ensure optimal treatment. In particular, this risk–benefit approach should seek to identify patients with aggressive disease, and, within a multidisciplinary setting, balance the likelihood of treatment success with the probability of treatment-related adverse effects.
Literatur
1.
Zurück zum Zitat Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomark Prev. 2009;18:784–91. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomark Prev. 2009;18:784–91.
2.
Zurück zum Zitat Horn-Ross PL, Lichtensztajn DY, Clarke CA, et al. Continued rapid increase in thyroid cancer incidence in California: trends by patient, tumor, and neighborhood characteristics. Cancer Epidemiol Biomark Prev. 2014;23:1067–79. Horn-Ross PL, Lichtensztajn DY, Clarke CA, et al. Continued rapid increase in thyroid cancer incidence in California: trends by patient, tumor, and neighborhood characteristics. Cancer Epidemiol Biomark Prev. 2014;23:1067–79.
3.
Zurück zum Zitat Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer. 1997;79:564–73.PubMed Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer. 1997;79:564–73.PubMed
4.
Zurück zum Zitat Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306.PubMed Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306.PubMed
5.
Zurück zum Zitat McLeod DS. Thyrotropin in the development and management of differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2014;43:367–83.PubMed McLeod DS. Thyrotropin in the development and management of differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2014;43:367–83.PubMed
8.
Zurück zum Zitat McLeod DS, Sawka AM, Cooper DS. Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet. 2013;381:1046–57.PubMed McLeod DS, Sawka AM, Cooper DS. Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet. 2013;381:1046–57.PubMed
9.
Zurück zum Zitat Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.PubMed Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.PubMed
10.
Zurück zum Zitat Beahrs OH, Myers MH. Manual for staging of cancer. 2nd ed. Philadelphia: Lippincott; 1983. Beahrs OH, Myers MH. Manual for staging of cancer. 2nd ed. Philadelphia: Lippincott; 1983.
11.
Zurück zum Zitat Greene FL, Trotti A, Fritz AG, et al. Thyroid. In: Greene FL, Trotti A, Fritz AG, Compton CC, Byrd DR, Edge SB, editors. AJCC cancer staging handbook. 7th ed. Chicago: American Joint Committee on Cancer; 2010. p. 111–22. Greene FL, Trotti A, Fritz AG, et al. Thyroid. In: Greene FL, Trotti A, Fritz AG, Compton CC, Byrd DR, Edge SB, editors. AJCC cancer staging handbook. 7th ed. Chicago: American Joint Committee on Cancer; 2010. p. 111–22.
12.
Zurück zum Zitat Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–53.PubMed Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–53.PubMed
13.
Zurück zum Zitat Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery. 1994;116:1036–40 (discussion 40–1).PubMed Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery. 1994;116:1036–40 (discussion 40–1).PubMed
14.
Zurück zum Zitat Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998;83:1012–21.PubMed Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998;83:1012–21.PubMed
15.
Zurück zum Zitat Beenken S, Roye D, Weiss H, et al. Extent of surgery for intermediate-risk well-differentiated thyroid cancer. Am J Surg. 2000;179:51–6.PubMed Beenken S, Roye D, Weiss H, et al. Extent of surgery for intermediate-risk well-differentiated thyroid cancer. Am J Surg. 2000;179:51–6.PubMed
16.
Zurück zum Zitat Oyer SL, Smith VA, Lentsch EJ. Reevaluating the prognostic significance of age in differentiated thyroid cancer. Otolaryngol Head Neck Surg. 2012;147:221–6.PubMed Oyer SL, Smith VA, Lentsch EJ. Reevaluating the prognostic significance of age in differentiated thyroid cancer. Otolaryngol Head Neck Surg. 2012;147:221–6.PubMed
17.
Zurück zum Zitat Amphlett B, Lawson Z, Abdulrahman GO Jr, et al. Recent trends in the incidence, geographical distribution, and survival from thyroid cancer in Wales, 1985–2010. Thyroid. 2013;23:1470–8.PubMed Amphlett B, Lawson Z, Abdulrahman GO Jr, et al. Recent trends in the incidence, geographical distribution, and survival from thyroid cancer in Wales, 1985–2010. Thyroid. 2013;23:1470–8.PubMed
18.
Zurück zum Zitat Bischoff LA, Curry J, Ahmed I, et al. Is above age 45 appropriate for upstaging well-differentiated papillary thyroid cancer? Endocr Pract. 2013;19:995–7.PubMed Bischoff LA, Curry J, Ahmed I, et al. Is above age 45 appropriate for upstaging well-differentiated papillary thyroid cancer? Endocr Pract. 2013;19:995–7.PubMed
19.
Zurück zum Zitat Banerjee M, Muenz DG, Chang JT, et al. Tree-based model for thyroid cancer prognostication. J Clin Endocrinol Metab. 2014;99:3737–45.PubMed Banerjee M, Muenz DG, Chang JT, et al. Tree-based model for thyroid cancer prognostication. J Clin Endocrinol Metab. 2014;99:3737–45.PubMed
20.
Zurück zum Zitat Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol. 2012;19:1874–80.PubMed Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol. 2012;19:1874–80.PubMed
21.
Zurück zum Zitat Andersen PE, Kinsella J, Loree TR, et al. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg. 1995;170:467–70.PubMed Andersen PE, Kinsella J, Loree TR, et al. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg. 1995;170:467–70.PubMed
22.
Zurück zum Zitat Ronga G, Filesi M, Montesano T, et al. Lung metastases from differentiated thyroid carcinoma. A 40 years’ experience. Q J Nucl Med Mol Imaging. 2004;48:12–9.PubMed Ronga G, Filesi M, Montesano T, et al. Lung metastases from differentiated thyroid carcinoma. A 40 years’ experience. Q J Nucl Med Mol Imaging. 2004;48:12–9.PubMed
23.
Zurück zum Zitat Haymart MR. Understanding the relationship between age and thyroid cancer. Oncologist. 2009;14:216–21.PubMed Haymart MR. Understanding the relationship between age and thyroid cancer. Oncologist. 2009;14:216–21.PubMed
24.
Zurück zum Zitat Park HS, Roman SA, Sosa JA. Treatment patterns of aging Americans with differentiated thyroid cancer. Cancer. 2010;116:20–30.PubMed Park HS, Roman SA, Sosa JA. Treatment patterns of aging Americans with differentiated thyroid cancer. Cancer. 2010;116:20–30.PubMed
25.
Zurück zum Zitat Machens A, Dralle H. Age disparities in referrals to specialist surgical care for papillary thyroid cancer. Eur J Surg Oncol. 2009;35:1312–7.PubMed Machens A, Dralle H. Age disparities in referrals to specialist surgical care for papillary thyroid cancer. Eur J Surg Oncol. 2009;35:1312–7.PubMed
26.
27.
Zurück zum Zitat Randolph GW, Doherty GM. Carcinoma of the follicular thyroid: surgical therapy. In: Braverman LE, Cooper DS, editors. Werner & Ingbar’s the thyroid: a fundamental and clinical text. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 702–11. Randolph GW, Doherty GM. Carcinoma of the follicular thyroid: surgical therapy. In: Braverman LE, Cooper DS, editors. Werner & Ingbar’s the thyroid: a fundamental and clinical text. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 702–11.
28.
Zurück zum Zitat Bliss R, Patel N, Guinea A, et al. Age is no contraindication to thyroid surgery. Age Ageing. 1999;28:363–6.PubMed Bliss R, Patel N, Guinea A, et al. Age is no contraindication to thyroid surgery. Age Ageing. 1999;28:363–6.PubMed
29.
Zurück zum Zitat Passler C, Avanessian R, Kaczirek K, et al. Thyroid surgery in the geriatric patient. Arch Surg. 2002;137:1243–8.PubMed Passler C, Avanessian R, Kaczirek K, et al. Thyroid surgery in the geriatric patient. Arch Surg. 2002;137:1243–8.PubMed
30.
Zurück zum Zitat Seybt MW, Khichi S, Terris DJ. Geriatric thyroidectomy: safety of thyroid surgery in an aging population. Arch Otolaryngol Head Neck Surg. 2009;135:1041–4.PubMed Seybt MW, Khichi S, Terris DJ. Geriatric thyroidectomy: safety of thyroid surgery in an aging population. Arch Otolaryngol Head Neck Surg. 2009;135:1041–4.PubMed
31.
Zurück zum Zitat Raffaelli M, Bellantone R, Princi P, et al. Surgical treatment of thyroid diseases in elderly patients. Am J Surg. 2010;200:467–72.PubMed Raffaelli M, Bellantone R, Princi P, et al. Surgical treatment of thyroid diseases in elderly patients. Am J Surg. 2010;200:467–72.PubMed
32.
Zurück zum Zitat Lang BH, Lo CY. Total thyroidectomy for multinodular goiter in the elderly. Am J Surg. 2005;190:418–23.PubMed Lang BH, Lo CY. Total thyroidectomy for multinodular goiter in the elderly. Am J Surg. 2005;190:418–23.PubMed
33.
Zurück zum Zitat Sosa JA, Mehta PJ, Wang TS, et al. A population-based study of outcomes from thyroidectomy in aging Americans: at what cost? J Am Coll Surg. 2008;206:1097–105.PubMed Sosa JA, Mehta PJ, Wang TS, et al. A population-based study of outcomes from thyroidectomy in aging Americans: at what cost? J Am Coll Surg. 2008;206:1097–105.PubMed
34.
Zurück zum Zitat Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228:320–30.PubMedCentralPubMed Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228:320–30.PubMedCentralPubMed
35.
Zurück zum Zitat Tuggle CT, Park LS, Roman S, et al. Rehospitalization among elderly patients with thyroid cancer after thyroidectomy are prevalent and costly. Ann Surg Oncol. 2010;17:2816–23.PubMed Tuggle CT, Park LS, Roman S, et al. Rehospitalization among elderly patients with thyroid cancer after thyroidectomy are prevalent and costly. Ann Surg Oncol. 2010;17:2816–23.PubMed
36.
Zurück zum Zitat Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.PubMed Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.PubMed
37.
Zurück zum Zitat Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.PubMed Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.PubMed
38.
Zurück zum Zitat Pitoia F, Ward L, Wohllk N, et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2009;53:884–97.PubMed Pitoia F, Ward L, Wohllk N, et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2009;53:884–97.PubMed
39.
Zurück zum Zitat Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81(Suppl 1):1–122.PubMed Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81(Suppl 1):1–122.PubMed
41.
Zurück zum Zitat Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993;328:553–9.PubMed Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993;328:553–9.PubMed
42.
Zurück zum Zitat Hayes Cady B, Lecture Martin. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg. 1997;174:462–8. Hayes Cady B, Lecture Martin. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg. 1997;174:462–8.
43.
Zurück zum Zitat Shaha A. Treatment of thyroid cancer based on risk groups. J Surg Oncol. 2006;94:683–91.PubMed Shaha A. Treatment of thyroid cancer based on risk groups. J Surg Oncol. 2006;94:683–91.PubMed
44.
Zurück zum Zitat Wang LY, Palmer FL, Thomas D, et al. Preoperative neck ultrasound in clinical node-negative differentiated thyroid cancer. J Clin Endocrinol Metab. 2014;99:3686–93.PubMed Wang LY, Palmer FL, Thomas D, et al. Preoperative neck ultrasound in clinical node-negative differentiated thyroid cancer. J Clin Endocrinol Metab. 2014;99:3686–93.PubMed
45.
Zurück zum Zitat Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249–52.PubMed Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249–52.PubMed
46.
Zurück zum Zitat Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95:186–93.PubMed Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95:186–93.PubMed
47.
Zurück zum Zitat Abonowara A, Quraishi A, Sapp JL, et al. Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer. Clin Invest Med. 2012;35:E152–6.PubMed Abonowara A, Quraishi A, Sapp JL, et al. Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer. Clin Invest Med. 2012;35:E152–6.PubMed
48.
Zurück zum Zitat Klein Hesselink EN, Klein Hesselink MS, de Bock GH, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol. 2013;31:4046–53.PubMed Klein Hesselink EN, Klein Hesselink MS, de Bock GH, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol. 2013;31:4046–53.PubMed
49.
Zurück zum Zitat Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1993;77:334–8.PubMed Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1993;77:334–8.PubMed
50.
Zurück zum Zitat Biondi B, Fazio S, Carella C, et al. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1994;78:1028–33.PubMed Biondi B, Fazio S, Carella C, et al. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1994;78:1028–33.PubMed
51.
Zurück zum Zitat Mercuro G, Panzuto MG, Bina A, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab. 2000;85:159–64.PubMed Mercuro G, Panzuto MG, Bina A, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab. 2000;85:159–64.PubMed
52.
Zurück zum Zitat Kung AW, Yeung SS. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab. 1996;81:1232–6.PubMed Kung AW, Yeung SS. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab. 1996;81:1232–6.PubMed
53.
Zurück zum Zitat Sugitani I, Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery. 2011;150:1250–7.PubMed Sugitani I, Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery. 2011;150:1250–7.PubMed
54.
Zurück zum Zitat Bauer DC, Ettinger B, Nevitt MC, et al. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 2001;134:561–8.PubMed Bauer DC, Ettinger B, Nevitt MC, et al. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 2001;134:561–8.PubMed
55.
Zurück zum Zitat Randell AG, Nguyen TV, Bhalerao N, et al. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int. 2000;11:460–6.PubMed Randell AG, Nguyen TV, Bhalerao N, et al. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int. 2000;11:460–6.PubMed
56.
Zurück zum Zitat Gregerman RI, Gaffney GW, Shock NW, et al. Thyroxine turnover in euthyroid man with special reference to changes with age. J Clin Invest. 1962;41:2065–74.PubMedCentralPubMed Gregerman RI, Gaffney GW, Shock NW, et al. Thyroxine turnover in euthyroid man with special reference to changes with age. J Clin Invest. 1962;41:2065–74.PubMedCentralPubMed
57.
Zurück zum Zitat Cunningham JJ, Barzel US. Lean body mass is a predictor of the daily requirement for thyroid hormone in older men and women. J Am Geriatr Soc. 1984;32:204–7.PubMed Cunningham JJ, Barzel US. Lean body mass is a predictor of the daily requirement for thyroid hormone in older men and women. J Am Geriatr Soc. 1984;32:204–7.PubMed
58.
Zurück zum Zitat Rosenbaum RL, Barzel US. Levothyroxine replacement dose for primary hypothyroidism decreases with age. Ann Intern Med. 1982;96:53–5.PubMed Rosenbaum RL, Barzel US. Levothyroxine replacement dose for primary hypothyroidism decreases with age. Ann Intern Med. 1982;96:53–5.PubMed
59.
Zurück zum Zitat Kim M, Ladenson P. Thyroid. In: Goldman L, Schafer AI, editors. Goldman’s Cecil medicine. 24th ed. Philadelphia: Elsevier Saunders; 2012. p. 1450–63. Kim M, Ladenson P. Thyroid. In: Goldman L, Schafer AI, editors. Goldman’s Cecil medicine. 24th ed. Philadelphia: Elsevier Saunders; 2012. p. 1450–63.
60.
Zurück zum Zitat Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229–42.PubMed Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229–42.PubMed
61.
Zurück zum Zitat Carhill A, Litofsky D, Ain KB, et al. Long-term moderate thyroid hormone suppression therapy is associated with improved outcomes in differentiated thyroid carcinoma: National Thyroid Cancer Treatment Cooperative Study Group Registry analysis 1987–2012 [abstract]. Thyroid. 2014;24:A-6. Carhill A, Litofsky D, Ain KB, et al. Long-term moderate thyroid hormone suppression therapy is associated with improved outcomes in differentiated thyroid carcinoma: National Thyroid Cancer Treatment Cooperative Study Group Registry analysis 1987–2012 [abstract]. Thyroid. 2014;24:A-6.
62.
Zurück zum Zitat Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am. 2014;43:401–21.PubMed Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am. 2014;43:401–21.PubMed
63.
Zurück zum Zitat Jonklaas J, Nogueras-Gonzalez G, Munsell M, et al. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab. 2012;97:E878–87.PubMedCentralPubMed Jonklaas J, Nogueras-Gonzalez G, Munsell M, et al. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab. 2012;97:E878–87.PubMedCentralPubMed
64.
Zurück zum Zitat Tuttle RM, Lopez N, Leboeuf R, et al. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid. 2010;20:257–63.PubMed Tuttle RM, Lopez N, Leboeuf R, et al. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid. 2010;20:257–63.PubMed
65.
Zurück zum Zitat Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9.PubMed Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9.PubMed
66.
Zurück zum Zitat Sisson JC, Freitas J, McDougall IR, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011;21:335–46.PubMed Sisson JC, Freitas J, McDougall IR, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011;21:335–46.PubMed
67.
Zurück zum Zitat Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674–85.PubMed Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674–85.PubMed
68.
Zurück zum Zitat Burns JA, Morgenstern KE, Cahill KV, et al. Nasolacrimal obstruction secondary to I(131) therapy. Ophthal Plast Reconstr Surg. 2004;20:126–9.PubMed Burns JA, Morgenstern KE, Cahill KV, et al. Nasolacrimal obstruction secondary to I(131) therapy. Ophthal Plast Reconstr Surg. 2004;20:126–9.PubMed
69.
Zurück zum Zitat Van Nostrand D. Sialoadenitis secondary to (1)(3)(1)I therapy for well-differentiated thyroid cancer. Oral Dis. 2011;17:154–61.PubMed Van Nostrand D. Sialoadenitis secondary to (1)(3)(1)I therapy for well-differentiated thyroid cancer. Oral Dis. 2011;17:154–61.PubMed
70.
Zurück zum Zitat Iyer NG, Morris LG, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117:4439–46.PubMedCentralPubMed Iyer NG, Morris LG, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117:4439–46.PubMedCentralPubMed
71.
Zurück zum Zitat Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663–73.PubMed Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663–73.PubMed
72.
Zurück zum Zitat Holst JP, Burman KD, Atkins F, et al. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid. 2005;15:1321–31.PubMed Holst JP, Burman KD, Atkins F, et al. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid. 2005;15:1321–31.PubMed
73.
Zurück zum Zitat Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med. 2006;47:1587–91.PubMed Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med. 2006;47:1587–91.PubMed
74.
Zurück zum Zitat Taieb D, Sebag F, Cherenko M, et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf). 2009;71:115–23.PubMed Taieb D, Sebag F, Cherenko M, et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf). 2009;71:115–23.PubMed
75.
Zurück zum Zitat Wang TS, Cheung K, Mehta P, et al. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States. J Clin Endocrinol Metab. 2010;95:1672–80.PubMed Wang TS, Cheung K, Mehta P, et al. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States. J Clin Endocrinol Metab. 2010;95:1672–80.PubMed
76.
Zurück zum Zitat Mariotti S, Franceschi C, Cossarizza A, et al. The aging thyroid. Endocr Rev. 1995;16:686–715.PubMed Mariotti S, Franceschi C, Cossarizza A, et al. The aging thyroid. Endocr Rev. 1995;16:686–715.PubMed
77.
Zurück zum Zitat Kreisman SH, Hennessey JV. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med. 1999;159:79–82.PubMed Kreisman SH, Hennessey JV. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med. 1999;159:79–82.PubMed
78.
Zurück zum Zitat Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 1997;337:888–96.PubMed Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 1997;337:888–96.PubMed
79.
Zurück zum Zitat Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877–85.PubMed Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877–85.PubMed
80.
Zurück zum Zitat Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926–32.PubMed Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926–32.PubMed
81.
Zurück zum Zitat Hanscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47:648–54.PubMed Hanscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47:648–54.PubMed
82.
Zurück zum Zitat Tala H, Robbins R, Fagin JA, et al. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab. 2011;96:2105–11.PubMed Tala H, Robbins R, Fagin JA, et al. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab. 2011;96:2105–11.PubMed
83.
Zurück zum Zitat Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, et al. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid. 2012;22:310–7.PubMedCentralPubMed Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, et al. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid. 2012;22:310–7.PubMedCentralPubMed
84.
Zurück zum Zitat Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, et al. Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer. Endocr Pract. 2013;19:139–48.PubMed Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, et al. Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer. Endocr Pract. 2013;19:139–48.PubMed
85.
Zurück zum Zitat Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:457–80, x. Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:457–80, x.
86.
Zurück zum Zitat Sacks W, Fung CH, Chang JT, et al. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20:1235–45.PubMed Sacks W, Fung CH, Chang JT, et al. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20:1235–45.PubMed
87.
Zurück zum Zitat Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–28.PubMed Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–28.PubMed
88.
Zurück zum Zitat Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med. 1998;129:622–7.PubMed Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med. 1998;129:622–7.PubMed
89.
Zurück zum Zitat Terezakis SA, Lee KS, Ghossein RA, et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2009;73:795–801.PubMed Terezakis SA, Lee KS, Ghossein RA, et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2009;73:795–801.PubMed
90.
Zurück zum Zitat Schwartz DL, Lobo MJ, Ang KK, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 2009;74:1083–91.PubMedCentralPubMed Schwartz DL, Lobo MJ, Ang KK, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 2009;74:1083–91.PubMedCentralPubMed
91.
Zurück zum Zitat Riemann B, Kramer JA, Schmid KW, et al. Risk stratification of patients with locally aggressive differentiated thyroid cancer. Results of the MSDS trial. Nuklearmedizin. 2010;49:79–84. Riemann B, Kramer JA, Schmid KW, et al. Risk stratification of patients with locally aggressive differentiated thyroid cancer. Results of the MSDS trial. Nuklearmedizin. 2010;49:79–84.
92.
Zurück zum Zitat Brose MS, Smit J, Capdevila J, et al. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Rev Anticancer Ther. 2012;12:1137–47.PubMed Brose MS, Smit J, Capdevila J, et al. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Rev Anticancer Ther. 2012;12:1137–47.PubMed
93.
Zurück zum Zitat Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013;34:439–55.PubMedCentralPubMed Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013;34:439–55.PubMedCentralPubMed
94.
Zurück zum Zitat Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008;18:317–23.PubMed Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008;18:317–23.PubMed
95.
Zurück zum Zitat Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26:4708–13.PubMed Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26:4708–13.PubMed
96.
Zurück zum Zitat Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714–9.PubMedCentralPubMed Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714–9.PubMedCentralPubMed
97.
Zurück zum Zitat Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675–84.PubMedCentralPubMed Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675–84.PubMedCentralPubMed
98.
Zurück zum Zitat Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31–42.PubMed Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31–42.PubMed
99.
Zurück zum Zitat Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16:5260–8.PubMedCentralPubMed Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16:5260–8.PubMedCentralPubMed
100.
Zurück zum Zitat Sherman SI, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) [abstract]. J Clin Oncol. 2011;29 suppl:abstr 5503. Sherman SI, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) [abstract]. J Clin Oncol. 2011;29 suppl:abstr 5503.
101.
Zurück zum Zitat Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319–28.PubMedCentralPubMed Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319–28.PubMedCentralPubMed
102.
Zurück zum Zitat Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621–30.PubMed Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621–30.PubMed
103.
Zurück zum Zitat Kapiteijn E, Schneider TC, Morreau H, et al. New treatment modalities in advanced thyroid cancer. Ann Oncol. 2012;23:10–8.PubMed Kapiteijn E, Schneider TC, Morreau H, et al. New treatment modalities in advanced thyroid cancer. Ann Oncol. 2012;23:10–8.PubMed
104.
Zurück zum Zitat Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2664–71.PubMedCentralPubMed Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2664–71.PubMedCentralPubMed
105.
Zurück zum Zitat Dadu R, Waguespack SG, Sherman SI, et al. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014;19:477–82.PubMedCentralPubMed Dadu R, Waguespack SG, Sherman SI, et al. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014;19:477–82.PubMedCentralPubMed
106.
Zurück zum Zitat Yun KJ, Kim W, Kim EH, et al. Accelerated disease progression after discontinuation of sorafenib in a patient with metastatic papillary thyroid cancer. Endocrinol Metab (Seoul). 2014;29:388–93.PubMedCentralPubMed Yun KJ, Kim W, Kim EH, et al. Accelerated disease progression after discontinuation of sorafenib in a patient with metastatic papillary thyroid cancer. Endocrinol Metab (Seoul). 2014;29:388–93.PubMedCentralPubMed
107.
Zurück zum Zitat Carhill AA, Cabanillas ME, Jimenez C, et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013;98:31–42.PubMedCentralPubMed Carhill AA, Cabanillas ME, Jimenez C, et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013;98:31–42.PubMedCentralPubMed
108.
Zurück zum Zitat Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368:623–32.PubMedCentralPubMed Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368:623–32.PubMedCentralPubMed
Metadaten
Titel
Optimal Differentiated Thyroid Cancer Management in the Elderly
verfasst von
Donald S. A. McLeod
Kelly Carruthers
Dev A. S. Kevat
Publikationsdatum
01.04.2015
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 4/2015
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-015-0256-y

Weitere Artikel der Ausgabe 4/2015

Drugs & Aging 4/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.